News

As increased diversity of patient populations who participate in clinical trials becomes more entrenched as a modern business, clinical, and regulatory requirement, new trial technologies and tools...

Emerging technologies are making waves in biopharma research. A recent article in Citeline In Vivo discusses how machine learning (ML) is being used to improve clinical trial diversity. By analyzing...

Rohit Nambisam is CEO of Lokavant, OSP caught up with him at DIA Global in Boston earlier this summer to find out more about him and the work he is passionate about.

New analytics technology reduces trial costs and timelines; initial case shows it can cut the number of sites needed for a trial by 36% Lokavant, the clinical trial intelligence platform company,...

Attempts at improving diversity, equity, and inclusion (DEI) access across U.S. healthcare is a much-welcomed, if not long-overdue, development in recent years. SubstantiveDEI legislation was signed...

Lokavant CEO Rohit Nambisan recently joined Jared Taylor, host of BioBreakthrough, for an enlightening conversation about the unique challenges and exciting opportunities in the field of clinical...

Clinical trial participation amongst minority groups in the U.S. is woefully inadequate a challenge that has plagued this industry for years. In December 2022, substantive diversity, equity, and...

Attempts at improving diversity, equity, and inclusion (DEI) access across US healthcare is a much-welcomed, if not long-overdue, development in recent years. Substantive DEI legislation was signed...

In the latest episode of Brad Hightower's Note to File Podcast, Lokavant CEO Rohit Nambisan engaged in an enlightening conversation about the evolution of clinical trials. The discussion was...

The year 2020 was a watershed moment for many reasons, but notably, it cast a light on the pervasive health and social inequities that have long marred the U.S. The COVID-19 pandemic hit diverse...